pharma news

Jul 15, 2021

Hepion Pharma's NASH drug is set for Phase 2b after clearing the safety bar Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic drugs for the liver disease treatment arising from non-alcoholic steatohepatitis (NASH), declaring positive topline results from...

Jul 08, 2021

UNITY Biotechnology declares positive data from phase 1 clinical trial of UBX1325 in Advanced Vascular Eye Disease patients  UNITY Biotechnology, Inc., a biotechnology company developing therapeutics to decrease, impede, or reverse diseases of aging, declared positive data from its Phase 1 safety study of U...

Jul 06, 2021

Arrowhead Halts its ARO-ENaC Phase 1/2 Clinical Trial  Arrowhead Pharmaceuticals recently notified about its voluntary decision to put a pause on its ongoing Phase 1/2 clinical study of ARO-ENaC for patients with cystic fibrosis (CF). The announcement came after a preliminary update from an ongoing chronic ...

Jun 24, 2021

Insilico Medicine raises USD 255 Million for AI drug discovery Insilico Medicine, a Hong Kong-based global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, closed a USD 255 Million Series C financing. Warburg Pincus led the round with parti...

Jun 17, 2021

Mallinckrodt earns FDA nod for regenerative skin therapy for burns Mallinckrodt plc’s Stratagraft gained FDA approval for use in deep partial-thickness thermal burns. The company said regenerative skin tissue therapy could lessen or eliminate the requirement of autografting of healthy skin to treat burn wounds. ...

Jun 10, 2021

Aelis Farma pockets USD 30 Million upfront in cannabis use disorder deal with Indivior Indivior speculates that Aelis Farma has what it takes to bring cannabis use disorder therapy into the clinic with a USD 30 million upfront rights agreement. Aelis, clinical-stage French biotech zeroed in on brain disorders...

Jun 08, 2021

Verdict for Biogen’s Long-Awaited Alzheimer’s Drug Is Finally Here   The USFDA finally gave approval to eagerly-anticipated Biogen’s Drug Aducanumab for the treatment of Alzheimer’s disease under the accelerated approval pathway. The drug, marketed under the name Aduhelm, is the first that treats an un...

Jun 03, 2021

Abbott receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System for Aortic Stenosis treatment  On May 17, 2021, Abbott received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™. This marks the minimal...

May 27, 2021

Pieris Pharmaceuticals declares Respiratory and Ophthalmology deal with Genentech Pieris, a clinical-stage biotechnology company, declared that it has entered into a multi-program research collaboration and license collaboration with Genentech, a member of the Roche Group, to discover, develop and commercialise ...

May 13, 2021

Lilly, MiNA ink agreement to upregulate proteins using RNA Eli Lilly will utilise the power of MiNA Therapeutics’ proprietary small activating RNA (saRNA) technology platform to develop five novel drug candidates against diseases across the company’s core areas of focus. Eli Lilly declared a drug development ...